Small molecule compounds have earned billions of dollars for the pharmaceutical industry. But as technology advanced and biologics became possible, some companies shifted their focus to develop those biologic drugs that could revolutionize the industry. With each success and failure, a reassessment of R&D investment seems to occur – how much faith should go into large molecules vs. small molecules?
Session: Determine Where the Industry is Headed and Why: Large vs. Small Molecules
Hear a debate from executives at Johnson & Johnson, Baxter Healthcare and Cangene Corporation on where the industry is headed and why. Attend our session and hear experts discuss where the money is going and why. Top speakers include: Weiguo Dai, Scientific Director, JOHNSON & JOHNSON, Mahesh Chaubal, Senior Director, Pharmaceutical R&D, BAXTER HEALTHCARE, Kevin Taylor, Vice President Business Development, CANGENE CORPORATION. To learn more about the sessions offered at this years event, download our brochure.
As a reader of the Drug Delivery Partnerships blog, you get a 15% discount off the standard rate when using code XP1878BLOG to register. We look forward to seeing you February 6-8 in San Diego, CA!